Study of GNC-077 for advanced gastrointestinal and other solid tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called GNC-077 for people with gastrointestinal or other solid tumors that have spread after standard treatments. Researchers want to see if the drug is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old (Phase Ia) or at least 18 (Phase Ib).
- You have a gastrointestinal or other solid tumor that has spread, and standard treatments have not worked.
- You have at least one tumor that can be seen on a scan.
- You have a stored tumor sample from a past biopsy or surgery.
- You are generally active and able to take care of yourself (ECOG score 0 or 1).
- You agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GNC-077 for people with advanced breast cancer or other solid tumors that have spread. It aims to see if the drug is safe and effective.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
This trial tests a new drug called GNC-077 for people with advanced non-small cell lung cancer or other solid tumors that have spread. It aims to see if the drug is safe and helps shrink tumors.
This is an early-stage study testing a new drug called GTB-5550 in people with advanced cancers that have spread. The study aims to find the right dose and see if the drug helps shrink tumors.
This trial tests a new drug called NP-101 for people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and see if it can shrink tumors.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.